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Abstract   
 
The impact of the COVID-19 pandemic extended to health, social and economic aspects of human life. The 
international failure to combat this crisis has left many countries suffering under the influence of successive waves of 
the pandemic. In this report, we present a private medical clinic's experience dealing with the COVID-19 epidemic in 
Iraq. The adopted protocol to treat COVID-19 patients has briefly been discussed with an estimated cost of treatment 
in the private sector. We found that most COVID-19 patients recovered from the disease, except for cases that were 
associated with co-morbidities. The cost of treatment in the private sector is expensive, and most infected people could 
not afford it without public sector support. 
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Background  
Many cases of Coronavirus infiltrated Iraq early; however, the 
first case's official announcement was in the city of Najaf in 
March 2020 [1]. Most Iraqis underestimated the epidemic and 
largely neglected prevention measures. Among the Iraqis, the 
infection was considered a social stigma that forced many to 
hide the infection [2]. Such social behavior contributed to the 
worsening of the infected cases and the spread of the epidemic 
quietly and dramatically throughout the country. The world was 
not ready to deal with such a huge pandemic [3], especially in 
countries like Iraq, where the health system is depleted and 
reeling under the influence of rampant corruption [4].  
     Failure to comply with preventive measures has made the 
public health institutions an active source of transmitting the 
infection to the clients. Most of the healthcare providers were 
infected with COVID-19 and became a carrier of infection in 
their communities. Most patients are reluctant to contact public 
health institutions and resort to private medical clinics for 
treatment away from the people's eyes and in search of safety 
and quality [5]. Our private clinic was among several other 
working clinics in Baquba city, Diyala province, in the 
Northeast of Iraq. Independently, out of 596, 193 [6] COVID-
19 positive Polymerase Chain Reaction (PCR) cases recorded in 
Iraq up to 31st December 2020, we received more than two 
thousand patients over the period from April to the end of 
December 2020. Our clinic had changed into a COVID-19 
clinic. 
Like published worldwide data, the mortality and morbidity 
rates were highest at the old age group; however, many 
mortalities were reported in the younger age group. Several 
reasons backed behind such high rates among Iraqis, including 
the limited capacity of the public health institutions and the 
steady increase in the prevalence of COVID-19 infection. Many 
families were forced to provide medication and oxygen therapy 
(O2) to their patients at their expense, which constituted an 
additional burden on those with limited income. Covid-19 is 
typically a biopsychosocial disease [7]. Psychological 
difficulties and prolonged fatigue are seen in less than a third of 
our clinic patients. Depression, sleeping difficulties, and anxiety 
are seen after recovering in about a fifth of patients regardless 
of age but correlated with lung involvement severity. 
     Depending on our experience in managing the Covid-19 
pandemic, patients presented with symptoms of an upper 
respiratory infection such as loss of smell and taste usually 
experience benign course compared to those presented with 
typical presentation such as high fever, shortness of breath, sore 
throat, cough, sneezing, runny nose, nasal congestion, sneezing, 
achy muscles, and headache. However, the more fatal and 
challenging situation when the infection progresses involves the 
lower respiratory system (airways and lungs). Symptoms may 
worsen, such as "severe productive cough, shortness of breath, 
chest tightness”. We found that the pulmonary in situ vascular 
thrombosis is a significant cause of late after cure mortality, so 
we extended the course of anticoagulants Eliquis (apixaban) and 
Xarelto (rivaroxaban) up to 30 days to reduce the likelihood of 
blood clotting and systemic embolism. Moreover, less likely 
cerebrovascular accident (CVA) or peripheral arterial 
thrombosis have been seen, and there is no evidence of deep 
venous thrombosis (DVT) have noted. Late or long-term 
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Sequelae has been reported among patients with prolonged 
hypoxia (weeks or months); however, no long-term fibrosis is 
seen in tuberculosis patients (TB) [8]. After six months from 
recovery, one patient still has exertional dyspnea and needs 
supplemental oxygen therapy at night. Chest X-ray shows 
residual fibrotic lesions, suggesting the possibility of long-term 
sequences. However, some cases presented with gastroenteritis, 
however elevation in the liver enzymes' level is not uncommon, 
but less than four folds associated with epigastric pain and 
vomiting.  
    Additionally, when COVID-19 being a systemic infection, 
some patients presented with arthritis, rash, pericardial effusion, 
severe hepatitis, nephritis, orchitis, thrombocytopenia, and 
Urinary tract infection (UTI). We here confirm what other 
literature indicated [9] that COVID-19 is diabetogenic, 
especially with dexamethasone regardless the age. The risk of 
coronavirus infection doubles for diabetics, and at the same 
time, new cases of diabetes have been recorded and the 
emergence of severe complications in preexisting diabetes due 
to Coronavirus infection. 
 
Private medical clinic protocol to treat COVID-19 patients    
There is no proven and effective antiviral therapy nor an 
efficient vaccine for COVID-19 infection based on our 
knowledge. Moreover, antibiotics are never of any benefit in 
changing the course of illness. The most effective interventions 
are Actemra (Tocilizumab), the Interleukin-6 (IL-6) receptor 
antagonists, convalescent plasma, anticoagulant, 
dexamethasone in addition to oxygen (O2) therapy. The IL-6 
has the potential of anti-cytokine storm ability by slowing down 
the systemic inflammatory response to viral infection in its 
early stages [10]. Table 1 shows the general protocol used to 
treat COVID-19 positive PCR cases. Most private clinics are 
concerned with conducting clinical and physical examination 
only, while the rest of the medications and therapies are taken 
from private pharmacies. Moreover, except for the PCR, and 
computed tomography (CT-scan) the patients depend on the 
private laboratories to perform the hematological, and the 
serological tests. However, several patients rely on private 
radiological clinics to confirm or exclude the COVID-19 via 
CT-scan when necessary.   
 
Estimated cost to treat COVID-19 patients at private clinics 
An average estimated cost was calculated for each COVID-19 
case treated in private clinics (Table 1). The average cost for a 
patient treated from Coronavirus in a range of five to ten days is 
approximately (IQD 573,228) (equivalent to USD 477.69, 
exchange rate 1 US Dollar (USD)= Iraqi  Dinar (IQD)1200 in 
November 2020 ). The cost is directly proportional to the period 
of treatment and the emergence of complications [11].  
     The patient who does not respond to simple protocol needs a 
more extended treatment period, such as continuous oxygen 
therapy for several weeks, or the need for further intervention, 
such as Actimera infusion (IL6 antagonist) when the IL6 is 
extremely high. In such cases, the total cost may rise to IQD 
3,173,232 (equivalent to USD 2,644.36) when Meropenem 
injection and Actimera infusion used to treat the severe and 
complicated cases. Local governments in Iraq provide free of 
charge oxygen for COVID-19 patients, however, citizens must 
buy oxygen bottles on their expense. The cost of one empty 
oxygen bottle about IQD 20,000 (equivalent to USD 16.67) in 
the private sector. Actimera infusion (IL-6 antagonist) is a 
lifesaving in severe and deteriorated COVID-19 cases, 
however, considering absence of the government support the 
drug is costly. A10 ml of  Actimera infusion may cost about 
IQD 2,250,000 (equivalent to USD 1875). The cost per doctor’s 
visit ranged between IQD 15,000 to 25,000 (equivalent to USD 
12.5 to 20.83). Nursing services for COVID-19 patients are 
essential to follow the treatment protocol at home. The cost per 
nurse’s visit about IQD 5000 (equivalent to USD 4.16).  
     This study complaint of several limitations. First, the lack of 
a national drug pricing policy in Iraq, the diversity of drug 
sources, and the absence of quality control program allowed for 
a wide gap in treatment costs to emerge. Therefore, the cost of 
treatment may change dramatically when the protocol switching 
from Ceftriaxone injection to Meropenem injection or when 
switching from a lesser quality product to a high-specification 
product. Second, elderly patients with chronic diseases are more 
likely to have complications that require a more extended 
treatment period. Moreover, some services are provided by the 
state for free, such as PCR, and CT-scan, and conversely, only 
the CT-scan costs about IQD 50,000 (equivalent to USD 41.67) 
in the private sector. Third, all the information regarding cost 
prices is approximate, depending on the private pharmacies' 
pricing in Iraq. Fourth, the study did not include other incurred 
costs such as transportation costs, food, time, and the cost 
related to job absenteeism of patient; therefore, we cannot claim 
an economic evaluation. The need to reform the Iraqi health 
system has become an urgent necessity through the 
implementation of effective health economic policies, such as 
the adoption of universal health insurance (UHI). Moreover, 
technical, and clinical systems such as the Diagnosis Related 
Group (DRG) or Case-mix are preferable systems that precisely 





More than 90.0% of the confirmed positive PCR COVID-19 
cases, which were undergone to management in our private 
clinic, made a full recovery at different times. However, very 
few real-second attacks have been recorded by new CT lesion 
after resolution and PCR positivity after becoming negative 
from the first attack. Treating COVID-19 patient in the private 
sector is expensive. There is a wide difference in the cost of 
treatment at the local level. The cost doubles with the length of 
treatment and the need for Actimera infusion (IL6 
antagonist).We are dealing with a fierce enemy that arose in 
mysterious circumstances and had the ability to change and 
attack other times. Therefore, what we say today about the way 




COVID-19: Coronavirus; PCR: Polymerase Chain Reaction; 
CT-scan:   Computed Tomography; CVA: Cerebrovascular 
Accident (CVA); DVT: Deep Venous Thrombosis; TB: 
Tuberculosis; UTI: Urinary Tract Infection; O2: Oxygen; IL-6: 
Interleukin-6; IQD: Iraqi Dinar; USD: United State Dollar  
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No. Therapy  Indication  Dose given Cost per item 
(IQD) 




1 Paracetamol Fever and aches 500mg X 3 750 Ten days 2,250 1.88 
2 Metoclopramide 
injection  
Nausea and vomiting 10 mg 1X 2  1,000 5 days 10,000 8.33 
3 Vitamin 
D3(Cholecalciferol) 
Supplementary  125mcg (50000 IU) 
X1  
12,000 2-4 weeks  12,000 10.00 
4  Intravenous fluid Dehydration and or 
diminished feeding 
N/S, GW5% (4 
liters) 
3,000 5 days 120, 000 100.00 
5 Rivaroxaban Thrombosis  
prophylaxis 
5-10 mg X 1 55,000 30 days 55,000 45.83 
6 O2 therapy Hypoxia  On need 2,0000 On need  20,000 16.67 
7 Dexamethasone 
injection 
Hypoxia  6 mg/2m  I.V. 3,000 Ten days 30,000 25.00 
8 Antibiotics:       
8a Ceftriaxone  
injection 
Infection  1gram i.v. x 2 6,000 7 days 84,000 70.00 
8b Meropenem 
injection 
Infection  1 gram i.v x 2 25,000 7 days 350,000 291.67 
8c Azithromycin 
(Zithromax) 
Infection  500 mg x 1 5,000 6 Days  5,000 4.16 
9 Actimera infusion 
(IL6 antiagonist)  
 Patient not responded, 
IL6 is very high  




1-2 times (on 
need) 
2,250,000 1,875.0 
10 Labrotuary tests  Full investigation  Repeated On 
need 
120,000 100.0 
11 Chest x-ray  Anterior/  posterior 20,000 Twice  40,000 33.33 
12 Fees paid to Doctor   Per visit 20,000 Twice  40,000 33.33 
13 Fees paid to Nurses   Per visit 5,000 Five times 35,000 29.16 
